2027, Biopharma and Food and Drug Administration

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2027

Biopharma

Food and Drug Administration

The future of targeted alpha therapy development and manufacture

European Pharmaceutical Review

MARCH 7, 2024

billion between 2022 to 2027. Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?

Manufacturing

Manufacturing Food and Drug Administration Marketing Management

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

APRIL 24, 2023

These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share.

Manufacturing

Manufacturing Food and Drug Administration Biopharma Sales

Pharma Rep Focus

The future of targeted alpha therapy development and manufacture

High biologics demand spurs need for greater contract manufacturing

Stay Connected